Methscopolamine
Active ingredient · 2 therapeutic classes
- Drug class
- Belladonna Alkaloids, Semisynthetic, Quaternary Ammonium Compounds
- Availability
- Prescription only
- Routes
- Oral
- Markets covered
- 1
- Products on record
- 2
Overview
Plain-language summary, compiled from the cited regulatory records
Methscopolamine is a medication classified as a Belladonna Alkaloid, Semisynthetic, and a Quaternary Ammonium Compound [1]. It is approved as adjunctive therapy for the treatment of peptic ulcer [1]. However, it is important to note that methscopolamine bromide has not been demonstrated to be effective in promoting the healing of peptic ulcers, reducing the frequency of their recurrence, or preventing complications associated with them [1].
This active ingredient is available under various brand names [1].
This is not medical advice. Consult a qualified healthcare professional.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| US United States | FDA | 2 | February 24, 2025 |
USUnited States· FDA
2 products
Uses
INDICATIONS AND USAGE
Adjunctive therapy for the treatment of peptic ulcer. METHSCOPOLAMINE BROMIDE HAS NOT BEEN SHOWN TO BE EFFECTIVE IN CONTRIBUTING TO THE HEALING OF PEPTIC ULCER, DECREASING THE RATE OF RECURRENCE OR PREVENTING COMPLICATIONS.
How to take
DOSAGE AND ADMINISTRATION
5 to 5 mg at bedtime. 5 mg daily will be clinically effective in most patients without the production of appreciable side effects. If the patient is experiencing symptoms such as severe abdominal pain or cramping which demand prompt relief, the drug may be started on a daily dosage of 20 mg, administered in doses of 5 mg one- half hour before meals and at bedtime.
If very unpleasant side effects develop promptly, the daily dosage should be reduced. If neither symptomatic relief nor side effects appear, the daily dosage may be increased. Some patients have tolerated 30 mg daily with no unpleasant reactions.
Patients whose dosage has been reduced to eliminate or modify side effects often continue to show adequate response both subjectively in relief of symptoms and objectively as measured by antisecretory effects. The ultimate aim of therapy is to arrive at a dosage which provides maximal clinical effectiveness with a minimum of unpleasant side effects.
Many patients report no side effects on a dosage which gives complete relief of symptoms. On the other hand, some patients have reported severe side effects without appreciable symptomatic relief. Such patients must be considered unsuited for this therapy.
Usually they have been or will prove to be similarly intolerant to other anticholinergic drugs. If methscopolamine bromide is to be used in a patient who gives a history of such intolerance, it should be started at a low dosage.
This is not medical advice. Consult a qualified healthcare professional.
Side effects & warnings
ADVERSE REACTIONS
The following adverse reactions have been observed, but there is not enough data to support an estimate of frequency.
Cardiovascular :
Tachycardia, palpitation.
Allergic :
Severe allergic reaction or drug idiosyncrasies including anaphylaxis.
CNS :
Headaches, nervousness, mental confusion, drowsiness, dizziness.
Special Senses :
Blurred vision, dilation of the pupil, cycloplegia, increased ocular tension, loss of taste.
Renal :
Urinary hesitancy and retention.
Gastrointestinal :
Nausea, vomiting, constipation, bloated feeling.
Dermatologic :
Decreased sweating, urticaria and other dermal manifestations.
Miscellaneous :
Xerostomia, weakness, insomnia, impotence, suppression of lactation.
WARNINGS
In the presence of high environmental temperature, heat prostration (fever and heat stroke due to decreased sweating) can occur with drug use. Diarrhea may be an early symptom of incomplete intestinal obstruction, especially in patients with ileostomy or colostomy.
In this instance treatment with this drug would be inappropriate and possibly harmful. Methscopolamine bromide may produce drowsiness or blurred vision. The patient should be cautioned regarding activities requiring mental alertness such as operating a motor vehicle or other machinery or performing hazardous work while taking this drug.
, neuromuscular blockade leading to muscular weakness and possible paralysis.
This is not medical advice. Consult a qualified healthcare professional.
Who should not take it
CONTRAINDICATIONS
, pyloroduodenal stenosis); paralytic ileus; intestinal atony of the elderly or debilitated patient; unstable cardiovascular status in acute hemorrhage; severe ulcerative colitis; toxic megacolon complicating ulcerative colitis; myasthenia gravis.
5 mg and 5 mg is contraindicated in patients who are hypersensitive to methscopolamine bromide or related drugs.
This is not medical advice. Consult a qualified healthcare professional.
Drug interactions
Known interactions involving Methscopolamine. Select one for details. This list is informational and not a complete interaction checker.
Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.
Sources & citations
- [1]FDA DailyMed · 14c0c030-e96d-4a… · revised February 24, 2025 [PDF]
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.